What do systematic reviews say?

TCAs with predominantly SRI actions vs other TCAs

• Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Low

Antioxidants vs placebo

• Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 6 participants
  Low

Antipsychotics vs placebo

• Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Low

Glutamate modulators vs placebo

Glutamate modulators showed no clear difference in tolerability of treatment ‐ dropouts due to adverse eventscDropout… compared with placebo (low certainty).

• Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
  RR 2.86 [0.12, 66.11]
  1 study · 39 participants
  Low

Selective serotonin reuptake inhibitors vs placebo

SSRIs showed no clear difference in tolerability of treatment ‐ dropouts due to adverse eventseDropout… compared with placebo (low certainty).

• Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
  RR 3 [0.33, 27.62]
  2 studies · 78 participants
  Low

TCAs with predominantly SRI actions vs placebo

It is very uncertain whether TCAs with predominantly SRI actions changes tolerability of treatment ‐ dropouts due to adverse eventsdDropout… compared with placebo (very low certainty).

• Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
  RR 4.45 [0.27, 73.81]
  1 study · 16 participants
  Very low

Sclerotherapy vs no intervention

It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).

• Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with… 2020 · Cochrane Headline outcomes only
  RR 2.48 [0.69, 8.84]
  1 study · 108 participants
  Very low

Pine bark extract vs placebo

The review found no eligible studies for this question.

• Pine bark (Pinus spp.) extract for treating chronic disorders 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Elemental formula supplements vs polymeric formula supplements

The review found no eligible studies for this question.

• Enteral nutrition for maintenance of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Urtoxazumab (3.0 mg/kg) vs placebo

Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 71 participants
  Low

Urtoxazumab (1.0 mg/kg) vs placebo

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 74 participants
  Low

Adverse events with anti‐gram‐positive antibiotics vs placebo

It is very uncertain whether adverse events with anti‐gram‐positive antibiotics changes any adverse events compared with placebo (very low certainty).

• Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer 2017 · Cochrane Headline outcomes only
  RR 1.74 [1.5, 2.01]
  9 studies · 1936 participants
  Very low

SDAC + hospital intervention vs hospital intervention

• First aid interventions by laypeople for acute oral poisoning 2018 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 4904 participants
  Very low

Prevention of UI after radical: one active treatment vs another active treatment (pre‐operative PFMT + electrical stimulation versus pre‐operative PFMT)

The review found no eligible studies for this question.

• Conservative management for postprostatectomy urinary incontinence 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 550 participants
  Very low

Benzbromarone vs probenecid

Benzbromarone may leads to lower total adverse events compared with probenecid (low certainty).

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  RR 0.43 [0.25, 0.74]
  2 studies · 129 participants
  Low

Benzbromarone vs allopurinol

Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  RR 3 [0.64, 14.16]
  1 study · 55 participants
  Low

Drospirenone plus ethinylestradiol vs placebo

Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).

• Oral contraceptives containing drospirenone for premenstrual syndrome 2023 · Cochrane Headline outcomes only
  OR 3.41 [2.01, 5.78]
  4 studies · 776 participants
  Low

One‐food elimination diet vs six‐food elimination diet

It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events compared with six‐food elimination diet (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 0.62 [0.11, 3.57]
  1 study · 129 participants
  Very low

Elemental formula supplements vs polymeric formula supplements

Elemental formula supplements showed no clear difference in withdrawals due to adverse events compared with polymeric formula supplements (low certainty).

• Enteral nutrition for maintenance of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 9.75 [0.59, 159.93]
  1 study · 33 participants
  Low